The ARK™ Linezolid Assay is a homogeneous enzyme immunoassay for the quantitative determination of linezolid in human serum on automated clinical chemistry analyzers. The measurements obtained are used in the monitoring of linezolid levels to help ensure appropriate therapy.
- Excellent precision, even in trough concentrations
- Fast and efficient routine monitoring for linezolid
- Liquid, ready-to-use reagents, calibrators and controls
- Storage at 2-8°C
- On-board stability for at least 60 days
- Does not contain any harmful preservatives, only ≤ 0,09% sodium azide
Linezolid [(S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide] is an oxazolidinone derivative with a predominantly bacteriostatic effect and the first of the oxazolidinone antibiotics to gain worldwide acceptance for treating severe infections caused by methicillin- or vancomycin- resistant gram-positive bacteria, as well as drug resistant tuberculosis
Treatment efficacy has been linked to two pharmacokinetic parameters – the ratio of the daily area under the plasma concentration curve to the minimum inhibitory concentration (AUC24/MIC), and the proportion of time that the plasma concentration is above the minimum inhibitory concentration (%T>MIC) for the organism. Because AUC and trough concentrations are highly correlated, measurements of trough linezolid concentrations (Cmin) have been used to ensure effective therapy.